Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is...
146 insider purchases on record · latest filing 2022-06-21.
Insiders have also filed 74 sale transactions at OGEN.